Positive effects of methylphenidate on hyperactivity are moderated by monoaminergic gene variants in children with autism spectrum disorders

J. T. McCracken, K. K. Badashova, D. J. Posey, M. G. Aman, L. Scahill, Elaine Tierney, L. E. Arnold, B. Vitiello, F. Whelan, S. Z. Chuang, M. Davies, B. Shah, C. J. McDougle, E. L. Nurmi

Research output: Contribution to journalArticle

Abstract

Methylphenidate (MPH) reduces hyperactive-impulsive symptoms common in children with autism spectrum disorders (ASDs), however, response and tolerability varies widely. We hypothesized monoaminergic gene variants may moderate MPH effects in ASD, as in typically developing children with attention-deficit/hyperactivity disorder. Genotype data were available for 64 children with ASD and hyperactivity who were exposed to MPH during a 1-week safety/tolerability lead-in phase and 58 who went on to be randomized to placebo and three doses of MPH during a 4-week blinded, crossover study. Outcome measures included the Clinical Global Impression-Improvement (CGI-I) scale and the Aberrant Behavior Checklist (ABC-hyperactivity index). A total of 14 subjects discontinued the study because of MPH side effects. Subjects were genotyped for variants in DRD1-DRD5, ADRA2A, SLC6A3, SLC6A4, MAOA and MAOB, and COMT. Forty-nine percent of the sample met positive responder criteria. In this modest but relatively homogeneous sample, significant differences by DRD1 (P=0.006), ADRA2A (P

Original languageEnglish (US)
Pages (from-to)295-302
Number of pages8
JournalPharmacogenomics Journal
Volume14
Issue number3
DOIs
StatePublished - 2014

Fingerprint

Methylphenidate
Genes
Attention Deficit Disorder with Hyperactivity
Checklist
Cross-Over Studies
Genotype
Placebos
Outcome Assessment (Health Care)
Autism Spectrum Disorder
Safety

Keywords

  • autism spectrum disorders
  • dopamine
  • genetics
  • hyperactivity
  • methylphenidate

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine
  • Genetics
  • Medicine(all)

Cite this

Positive effects of methylphenidate on hyperactivity are moderated by monoaminergic gene variants in children with autism spectrum disorders. / McCracken, J. T.; Badashova, K. K.; Posey, D. J.; Aman, M. G.; Scahill, L.; Tierney, Elaine; Arnold, L. E.; Vitiello, B.; Whelan, F.; Chuang, S. Z.; Davies, M.; Shah, B.; McDougle, C. J.; Nurmi, E. L.

In: Pharmacogenomics Journal, Vol. 14, No. 3, 2014, p. 295-302.

Research output: Contribution to journalArticle

McCracken, JT, Badashova, KK, Posey, DJ, Aman, MG, Scahill, L, Tierney, E, Arnold, LE, Vitiello, B, Whelan, F, Chuang, SZ, Davies, M, Shah, B, McDougle, CJ & Nurmi, EL 2014, 'Positive effects of methylphenidate on hyperactivity are moderated by monoaminergic gene variants in children with autism spectrum disorders', Pharmacogenomics Journal, vol. 14, no. 3, pp. 295-302. https://doi.org/10.1038/tpj.2013.23
McCracken, J. T. ; Badashova, K. K. ; Posey, D. J. ; Aman, M. G. ; Scahill, L. ; Tierney, Elaine ; Arnold, L. E. ; Vitiello, B. ; Whelan, F. ; Chuang, S. Z. ; Davies, M. ; Shah, B. ; McDougle, C. J. ; Nurmi, E. L. / Positive effects of methylphenidate on hyperactivity are moderated by monoaminergic gene variants in children with autism spectrum disorders. In: Pharmacogenomics Journal. 2014 ; Vol. 14, No. 3. pp. 295-302.
@article{ee8b64ef3a7840e6aebe09197a27c507,
title = "Positive effects of methylphenidate on hyperactivity are moderated by monoaminergic gene variants in children with autism spectrum disorders",
abstract = "Methylphenidate (MPH) reduces hyperactive-impulsive symptoms common in children with autism spectrum disorders (ASDs), however, response and tolerability varies widely. We hypothesized monoaminergic gene variants may moderate MPH effects in ASD, as in typically developing children with attention-deficit/hyperactivity disorder. Genotype data were available for 64 children with ASD and hyperactivity who were exposed to MPH during a 1-week safety/tolerability lead-in phase and 58 who went on to be randomized to placebo and three doses of MPH during a 4-week blinded, crossover study. Outcome measures included the Clinical Global Impression-Improvement (CGI-I) scale and the Aberrant Behavior Checklist (ABC-hyperactivity index). A total of 14 subjects discontinued the study because of MPH side effects. Subjects were genotyped for variants in DRD1-DRD5, ADRA2A, SLC6A3, SLC6A4, MAOA and MAOB, and COMT. Forty-nine percent of the sample met positive responder criteria. In this modest but relatively homogeneous sample, significant differences by DRD1 (P=0.006), ADRA2A (P",
keywords = "autism spectrum disorders, dopamine, genetics, hyperactivity, methylphenidate",
author = "McCracken, {J. T.} and Badashova, {K. K.} and Posey, {D. J.} and Aman, {M. G.} and L. Scahill and Elaine Tierney and Arnold, {L. E.} and B. Vitiello and F. Whelan and Chuang, {S. Z.} and M. Davies and B. Shah and McDougle, {C. J.} and Nurmi, {E. L.}",
year = "2014",
doi = "10.1038/tpj.2013.23",
language = "English (US)",
volume = "14",
pages = "295--302",
journal = "Pharmacogenomics Journal",
issn = "1470-269X",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Positive effects of methylphenidate on hyperactivity are moderated by monoaminergic gene variants in children with autism spectrum disorders

AU - McCracken, J. T.

AU - Badashova, K. K.

AU - Posey, D. J.

AU - Aman, M. G.

AU - Scahill, L.

AU - Tierney, Elaine

AU - Arnold, L. E.

AU - Vitiello, B.

AU - Whelan, F.

AU - Chuang, S. Z.

AU - Davies, M.

AU - Shah, B.

AU - McDougle, C. J.

AU - Nurmi, E. L.

PY - 2014

Y1 - 2014

N2 - Methylphenidate (MPH) reduces hyperactive-impulsive symptoms common in children with autism spectrum disorders (ASDs), however, response and tolerability varies widely. We hypothesized monoaminergic gene variants may moderate MPH effects in ASD, as in typically developing children with attention-deficit/hyperactivity disorder. Genotype data were available for 64 children with ASD and hyperactivity who were exposed to MPH during a 1-week safety/tolerability lead-in phase and 58 who went on to be randomized to placebo and three doses of MPH during a 4-week blinded, crossover study. Outcome measures included the Clinical Global Impression-Improvement (CGI-I) scale and the Aberrant Behavior Checklist (ABC-hyperactivity index). A total of 14 subjects discontinued the study because of MPH side effects. Subjects were genotyped for variants in DRD1-DRD5, ADRA2A, SLC6A3, SLC6A4, MAOA and MAOB, and COMT. Forty-nine percent of the sample met positive responder criteria. In this modest but relatively homogeneous sample, significant differences by DRD1 (P=0.006), ADRA2A (P

AB - Methylphenidate (MPH) reduces hyperactive-impulsive symptoms common in children with autism spectrum disorders (ASDs), however, response and tolerability varies widely. We hypothesized monoaminergic gene variants may moderate MPH effects in ASD, as in typically developing children with attention-deficit/hyperactivity disorder. Genotype data were available for 64 children with ASD and hyperactivity who were exposed to MPH during a 1-week safety/tolerability lead-in phase and 58 who went on to be randomized to placebo and three doses of MPH during a 4-week blinded, crossover study. Outcome measures included the Clinical Global Impression-Improvement (CGI-I) scale and the Aberrant Behavior Checklist (ABC-hyperactivity index). A total of 14 subjects discontinued the study because of MPH side effects. Subjects were genotyped for variants in DRD1-DRD5, ADRA2A, SLC6A3, SLC6A4, MAOA and MAOB, and COMT. Forty-nine percent of the sample met positive responder criteria. In this modest but relatively homogeneous sample, significant differences by DRD1 (P=0.006), ADRA2A (P

KW - autism spectrum disorders

KW - dopamine

KW - genetics

KW - hyperactivity

KW - methylphenidate

UR - http://www.scopus.com/inward/record.url?scp=84901287116&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901287116&partnerID=8YFLogxK

U2 - 10.1038/tpj.2013.23

DO - 10.1038/tpj.2013.23

M3 - Article

C2 - 23856854

AN - SCOPUS:84901287116

VL - 14

SP - 295

EP - 302

JO - Pharmacogenomics Journal

JF - Pharmacogenomics Journal

SN - 1470-269X

IS - 3

ER -